Related Experiment Video
Updated: Mar 20, 2026

Optimized Protocol for the Extraction of Proteins from the Human Mitral Valve
Published on: June 14, 2017
Differential MicroRNA Expression Profile in Myxomatous Mitral Valve Prolapse and Fibroelastic Deficiency Valves
Yei-Tsung Chen1,2, Juan Wang3,4, Abby S Y Wee5,6
1Cardiovascular Research Institute, National University Health System, Singapore 119228, Singapore. mdccyt@nus.edu.sg.
Abstract:
Myxomatous mitral valve prolapse (MMVP) and fibroelastic deficiency (FED) are two common variants of degenerative mitral valve disease (DMVD), which is a leading cause of mitral regurgitation worldwide. While pathohistological studies have revealed differences in extracellular matrix content in MMVP and FED, the molecular mechanisms underlying these two disease entities remain to be elucidated. By using surgically removed valvular specimens from MMVP and FED patients that were categorized on the basis of echocardiographic, clinical and operative findings, a cluster of microRNAs that expressed differentially were identified. The expressions of has-miR-500, -3174, -17, -1193, -646, -1273e, -4298, -203, -505, and -939 showed significant differences between MMVP and FED after applying Bonferroni correction (p < 0.002174). The possible involvement of microRNAs in the pathogenesis of DMVD were further suggested by the presences of in silico predicted target sites on a number of genes reported to be involved in extracellular matrix homeostasis and marker genes for cellular composition of mitral valves, including decorin (DCN), aggrecan (ACAN), fibromodulin (FMOD), α actin 2 (ACTA2), extracellular matrix protein 2 (ECM2), desmin (DES), endothelial cell specific molecule 1 (ESM1), and platelet/ endothelial cell adhesion molecule 1 (PECAM1), as well as inverse correlations of selected microRNA and mRNA expression in MMVP and FED groups. Our results provide evidence that distinct molecular mechanisms underlie MMVP and FED. Moreover, the microRNAs identified may be targets for the future development of diagnostic biomarkers and therapeutics.
Insights
Distinct microRNAs are involved in myxomatous mitral valve prolapse and fibroelastic deficiency, offering potential diagnostic biomarkers for degenerative mitral valve disease.
Area of Science:
- Cardiovascular Biology
- Molecular Genetics
- Biomarker Discovery
Background:
- Degenerative mitral valve disease (DMVD) causes mitral regurgitation globally.
- Myxomatous mitral valve prolapse (MMVP) and fibroelastic deficiency (FED) are key DMVD variants.
- Molecular mechanisms differentiating MMVP and FED are not fully understood.
Purpose of the Study:
- To identify molecular differences between MMVP and FED.
- To investigate the role of microRNAs in DMVD pathogenesis.
Main Methods:
- Analyzed surgically removed mitral valve specimens from MMVP and FED patients.
- Used differential microRNA expression profiling.
- Performed in silico prediction of microRNA target genes.
Main Results:
- Identified a cluster of significantly differentially expressed microRNAs between MMVP and FED (p < 0.002174).
- Predicted microRNA targets include genes involved in extracellular matrix homeostasis and valve cellularity.
- Observed inverse correlations between selected microRNA and mRNA expression.
Conclusions:
- Distinct molecular mechanisms underlie MMVP and FED.
- Identified microRNAs may serve as diagnostic biomarkers for DMVD.
- These microRNAs represent potential therapeutic targets for degenerative mitral valve disease.
More Related Videos
Related Concept Videos
Mitral Valve Prolapse I: Introduction
Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral Valve Prolapse II: Assessment and Management
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Mitral Stenosis I: Introduction
Mitral Regurgitation I: Introduction

